Tempus AI

Tempus AI is announcing a research platform that provides a de-identified, multimodal dataset of 100,000 whole genomes and associated longitudinal clinical data. The dataset will be integrated into Tempus' existing data environment and, via Tempus Lens, give researchers model-ready access to genomes, medical records, imaging and pathology. Early users can access it through an early-adopter program; general availability is planned for mid-2027, and the company aims to expand to one million genomes over the long term. » Więcej na de.investing.com

Piper Sandler upgraded Tempus AI from "Neutral" to "Overweight" and raised the price target from $56 to $76, after which the stock rose about 2.1% in premarket trading. The analyst cites three growth drivers: the planned acquisition of Personalis with a tumor‑informed MRD platform, the positive readout of the INTerpath‑001 study, and FDA approval of the tumor test xT CDx, which enables a uniform ADLT pricing. The test xF is also mentioned as a potential follow‑on product launch in the second half of 2027. » Więcej na de.investing.com

Tempus AI shares rose 2.7% in premarket trading after positive analyst comments accompanying the S-4 filing for the Personalis acquisition. Piper Sandler upgraded to "Overweight" and raised its price target from $56 to $76, while Canaccord reiterated a buy rating with an $80 target. The S-4 discloses a competitive sale process and underscores the strategic value of the deal. Tempus showed a move into profitability in the second quarter and raised its 2026 revenue forecast to about $1.6 billion. » Więcej na de.investing.com